Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of sotatercept in anemia associated with low- or intermediate-1 risk myelodysplastic syndromes
2012-002601-22Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sotatercept in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (6 arms), sponsored by Celgene Corporation. Primary endpoints: Rate of erythroid hematologic improvement and Late responder assessment. Started Jun 2013; status: completed.
02
Drugs
sotatercept
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2012-002601-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002601-22.